These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

663 related articles for article (PubMed ID: 29138342)

  • 21. Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?
    Zhongqi F; Xiaodong S; Yuguo C; Guoyue L
    Anticancer Agents Med Chem; 2019; 19(2):222-228. PubMed ID: 30426903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
    Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
    Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
    World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H; Shen J; Lu K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in immunotherapy for hepatocellular carcinoma.
    Sangro B; Sarobe P; Hervás-Stubbs S; Melero I
    Nat Rev Gastroenterol Hepatol; 2021 Aug; 18(8):525-543. PubMed ID: 33850328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potentiality of immunotherapy against hepatocellular carcinoma.
    Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
    World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges.
    Wang L; Wang FS
    Hepatol Int; 2019 Sep; 13(5):521-533. PubMed ID: 31352593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma.
    Seifi-Alan M; Shamsi R; Ghafouri-Fard S
    Immunotherapy; 2018 Apr; 10(5):411-421. PubMed ID: 29473472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
    Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy for hepatocellular carcinoma.
    Li S; Yang F; Ren X
    Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
    Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma.
    Lee SK; Lee SW; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy for hepatocellular carcinoma: Current and future.
    Johnston MP; Khakoo SI
    World J Gastroenterol; 2019 Jun; 25(24):2977-2989. PubMed ID: 31293335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
    Moreno-Cubero E; Larrubia JR
    World J Gastroenterol; 2016 Jul; 22(28):6469-83. PubMed ID: 27605882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy of Hepatocellular Carcinoma.
    Heinrich B; Czauderna C; Marquardt JU
    Oncol Res Treat; 2018; 41(5):292-297. PubMed ID: 29705790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status and perspectives of immune-based therapies for hepatocellular carcinoma.
    Aerts M; Benteyn D; Van Vlierberghe H; Thielemans K; Reynaert H
    World J Gastroenterol; 2016 Jan; 22(1):253-61. PubMed ID: 26755874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel immunotherapy strategies for hepatobiliary cancers.
    DeLeon TT; Zhou Y; Nagalo BM; Yokoda RT; Ahn DH; Ramanathan RK; Salomao MA; Aqel BA; Mahipal A; Bekaii-Saab TS; Borad MJ
    Immunotherapy; 2018 Sep; 10(12):1077-1091. PubMed ID: 30185133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
    Mizukoshi E; Nakamoto Y; Arai K; Yamashita T; Sakai A; Sakai Y; Kagaya T; Yamashita T; Honda M; Kaneko S
    Hepatology; 2011 Apr; 53(4):1206-16. PubMed ID: 21480325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update.
    Kudo M
    Oncology; 2017; 93 Suppl 1():147-159. PubMed ID: 29258079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.